Article Text

PDF

Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.
  1. C Milanese,
  2. A Salmaggi,
  3. L La Mantia,
  4. A Campi,
  5. M Eoli,
  6. M Savoiardo,
  7. G Bianchi,
  8. A Nespolo
  1. Department of Neurology, Istituto Neurologico C Besta, Milan, Italy.

    Abstract

    Sixteen patients with clinically definite MS admitted to a double blind randomised controlled trial of intrathecal natural beta-IFN were followed for a mean of 22 months including the six month treatment period. Clinical response, evaluated in terms of relapse frequency and of progression rate, showed an increase in relapse rate in treated patients during the six month treatment period and, overall, no benefit in treated versus placebo patients. Serial evaluations were made of cerebrospinal fluid (CSF) cells, IgG, myelin basic protein and CSF and blood T-cell subsets. A rise in CSF IgG Index, MBP and DR+ cells in IFN-treated patients suggested an activation of intrathecal immune response in treated patients.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.